Calcitonin Gene-Related Peptide (CGRP) Inhibitors Global Market Report 2025

The calcitonin gene-related peptide (CGRP) inhibitors market size has grown rapidly in recent years. It will grow from $2.87 billion in 2024 to $3.17 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to rising investments in research and development, an increase in the approval of new drugs, growing demand for non-opioid pain relievers, and a stronger emphasis on personalized medicine.

The calcitonin gene-related peptide (CGRP) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $4.68 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. Growth during the forecast period can be driven by the increasing prevalence of migraines, greater adoption of preventive migraine treatments, rising patient awareness, and higher healthcare expenditures. Key trends expected in the forecast period include advancements in drug formulation technologies, integration of digital health tools, progress in precision medicine, and technological improvements in biosimilars.

The rising occurrence of migraine is anticipated to contribute significantly to the growth of the calcitonin gene-related peptide (CGRP) inhibitors market in the coming years. Migraine is a severe type of headache characterized by pulsating pain, typically affecting one side of the head, and often accompanied by symptoms such as nausea, vomiting, and heightened sensitivity to light and sound. The increasing migraine cases are largely attributed to elevated stress levels, as ongoing stress activates certain neural pathways that can trigger migraine episodes. CGRP inhibitors play a key role in migraine management by providing a targeted and preventative treatment approach that fits both acute and long-term care strategies. These medications reduce the frequency and intensity of migraine attacks by effectively blocking CGRP receptors, leading to improved quality of life and enhanced daily performance. For example, in January 2023, the National Library of Medicine, a U.S.-based health information agency, reported that migraines affect between 14% and 15% of the global population and account for 4.9% of the global disease burden. Hence, the growing incidence of migraine is boosting demand in the CGRP inhibitors market.

Leading companies in the CGRP inhibitors space are investing in innovative therapies and seeking regulatory approvals for advanced treatment options, such as CGRP receptor antagonists, to enhance migraine relief, broaden clinical use, and provide user-friendly delivery methods like oral or intranasal formulations. A CGRP receptor antagonist is a type of medication that prevents migraine pain by inhibiting CGRP receptor activity. For instance, in April 2023, AbbVie Inc., a biotech firm based in the U.S., obtained approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) for the preventive treatment of chronic migraine in adults. QULIPTA is an oral CGRP receptor antagonist that works by blocking CGRP pathways involved in migraine pathogenesis, thereby reducing the occurrence of migraine episodes.

In October 2022, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Biohaven Pharmaceutical Holding Company Ltd. for roughly $11.6 billion. This acquisition was aimed at expanding Pfizer’s portfolio of migraine therapies and supporting long-term market growth by integrating Biohaven’s innovative CGRP-targeted treatments with Pfizer’s extensive global infrastructure. Biohaven Pharmaceutical Holding Company Ltd. is a U.S.-based biopharmaceutical firm known for its work in developing CGRP inhibitors for migraine management.

Major players in the calcitonin gene-related peptide (cgrp) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.

North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in calcitonin gene-related peptide (CGRP) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the calcitonin gene-related peptide (CGRP) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Calcitonin gene-related peptide (CGRP) inhibitors are a category of drugs that block the function of the CGRP pathway, which plays a role in transmitting pain and widening blood vessels in the brain. These inhibitors help to decrease both the frequency and intensity of migraines and are used as a treatment for patients suffering from chronic or episodic migraines.

The primary types of CGRP inhibitors include monoclonal antibodies, small molecules, and peptides. Monoclonal antibodies are lab-engineered molecules designed to bind specifically to a single target, such as a protein or receptor in the body. Their mechanisms of action involve anti-CGRP ligand therapies and CGRP receptor antagonists. Administration methods vary and include oral, nasal, and intravenous routes. Treatment options are categorized into preventive and acute therapies for migraines. End users of these treatments include hospitals, specialty clinics, mail-order pharmacies, and retail pharmacies.

The calcitonin gene-related peptide (CGRP) inhibitors market research report is one of a series of new reports that provides calcitonin gene-related peptide (CGRP) inhibitors market statistics, including calcitonin gene-related peptide (CGRP) inhibitors industry global market size, regional shares, competitors with a calcitonin gene-related peptide (CGRP) inhibitors market share, detailed calcitonin gene-related peptide (CGRP) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin gene-related peptide (CGRP) inhibitors industry. This calcitonin gene-related peptide (CGRP) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The calcitonin gene-related peptide (CGRP) inhibitors market consists of sales of aimovig, emgality, ubrogepant, rimegepant, atogepant, and ajovy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.